Beneficial effect of an antibody against interleukin-2 receptor (daclizumab) in an experimental model of hepatocyte xenotransplantation

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

304

HTML

1326

Figures (1-1)

222

Tables (1-3)

191

Sum=2043

Mar 7, 2007 (publication date) through Jul 21, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Mar 7, 2007; 13(9): 1435-1437
Published online Mar 7, 2007. doi: 10.3748/wjg.v13.i9.1435

Table 2 Histopathological analysis

Kruskal-Wallis: P = 0.001; Mann-Whitney:

^aP < 0.05 vs Dmab. FHF: fulminant hepatic failure.

Citation: Papagoras D, Papalois A, Tsaroucha A, Lytras D, Kyriazanos J, Giannakou N, Laftsidis P, Simopoulos C. Beneficial effect of an antibody against interleukin-2 receptor (daclizumab) in an experimental model of hepatocyte xenotransplantation. World J Gastroenterol 2007; 13(9): 1435-1437
URL: https://www.wjgnet.com/1007-9327/full/v13/i9/1435.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i9.1435